|
1
|
Thompson JC, Wood J and Feuer D: Prostate
cancer: Palliative care and pain relief. Br Med Bull. 83:341–354.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taichman RS, Loberg RD, Mehra R and Pienta
KJ: The evolving biology and treatment of prostate cancer. J Clin
Invest. 1179:2351–2361. 2007. View
Article : Google Scholar
|
|
3
|
Abate-Shen C and Shen MM: Molecular
genetics of prostate cancer. Genes Dev. 14:2410–2434. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chu DC, Chuang CK, Liou YF, Tzou RD, Lee
HC and Sun CF: The use of real-time quantitative PCR to detect
circulating prostate-specific membrane antigen mRNA in patients
with prostate carcinoma. Ann N Y Acad Sci. 1022:157–162. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parekh DJ, Ankerst DP, Troyer D,
Srivastava S and Thompson IM: Biomarkers for prostate cancer
detection. J Urol. 178:2252–2259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar-Sinha C and Chinnaiyan AM: Molecular
markers to identify patients at risk for recurrence after primary
treatment for prostate cancer. Urology. 62 Suppl 1:S19–S35. 2003.
View Article : Google Scholar
|
|
7
|
Tryggvadóttir L, Vidarsdóttir L,
Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar
T, Thorlacius S, Jonsson E, Eyfjord JE and Tulinius H: Prostate
cancer progression and aurvival in BRCA2 mutation carriers. J Natl
Cancer Inst. 99:929–935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liatsikos EN, Assimakopoulos K and
Stolzenburg JU: Quality of life after radical prostatectomy. Urol
Int. 80:226–230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gopalkrishnan RV, Kang DC and Fisher PB:
Molecular markers and determinants of prostate cancer metastasis. J
Cell Physiol. 189:245–256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Birdsey GM, Dryden NH, Amsellem V,
Gebhardt F, Sahnan K, Haskard DO, Dejana E, Mason JC and Randi AM:
Transcription factor Erg regulates angiogenesis and endothelial
apoptosis through VE-cadherin. Blood. 111:3498–3506. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Squire JA: TMPRSS2-ERG and PTEN loss in
prostate cancer. Nat Genet. 41:509–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mithal P, Allott E, Gerber L, Reid J,
Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury
JS, et al: PTEN loss in biopsy tissue predicts poor clinical
outcomes in prostate cancer. Int J Urol. 21:1209–1214. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaux A, Peskoe SB, Gonzalez-Roibon N,
Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA and Netto GJ:
Loss of PTEN expression is associated with increased risk of
recurrence after prostatectomy for clinically localized prostate
cancer. Mod Pathol. 25:1543–1549. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lotan TL, Carvalho FL, Peskoe SB, Hicks
JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, et
al: PTEN loss is associated with upgrading of prostate cancer from
biopsy to radical prostatectomy. Mod Pathol. 28:128–137. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chetram MA, Odero-Marah V and Hinton CV:
Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in
prostate cancer cells. Mol Cancer Res. 9:90–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singareddy R, Semaan L, Conley-Lacomb MK,
St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W,
et al: Transcriptional regulation of CXCR4 in prostate cancer:
Significance of TMPRSS2-ERG fusions. Mol Cancer Res. 11:1349–1361.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shore P, Whitmarsh AJ, Bhaskaran R, Davis
RJ, Waltho JP and Sharrocks AD: Determinants of DNA-binding
specificity of ETS-domain transcription factors. Mol Cell Biol.
16:3338–3349. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nhili R, Peixoto P, Depauw S, Flajollet S,
Dezitter X, Munde MM, Ismail MA, Kumar A, Farahat AA, Stephens CE,
et al: Targeting the DNA-binding activity of the human ERG
transcription factor using new heterocyclic dithiophene diamidines.
Nucleic Acids Res. 41:125–138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He J, Sun X, Shi T, Schepmoes AA, Fillmore
TL, Petyuk VA, Xie F, Zhao R, Gritsenko MA, Yang F, et al:
Antibody-independent targeted quantification of TMPRSS2-ERG fusion
protein products in prostate cancer. Mol Oncol. 8:1169–1180. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Srivastava A, Price DK and Figg WD:
Prostate tumor development and androgen receptor function
alterations in a new mouse model with ERG overexpression and PTEN
inactivation. Cancer Biol Ther. 15:1293–1295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Krohn A, Freudenthaler F, Harasimowicz S,
Kluth M, Fuchs S, Burkhardt L, Stahl PC, Tsourlakis M, Bauer M,
Tennstedt P, et al: Heterogeneity and chronology of PTEN deletion
and ERG fusion in prostate cancer. Mod Pathol. 27:1612–1620. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heselmeyer-Haddad KM, Garcia Berroa LY,
Bradley A, Hernandez L, Hu Y, Habermann JK, Dumke C, Thorns C,
Perner S, Pestova E, et al: Single-cell genetic analysis reveals
insights into clonal development of prostate cancers and indicates
loss of PTEN as a marker of poor prognosis. Am J Pathol.
184:2671–2686. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bock J, Mochmann LH, Schlee C,
Farhadi-Sartangi N, Göllner S, Müller-Tidow C and Baldus CD: ERG
transcriptional networks in primary acute leukemia cells implicate
a role for ERG in deregulated kinase signaling. PLoS One.
8:e528722013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mochmann LH, Neumann M, von der Heide EK,
Nowak V, Kühl AA, Ortiz-Tanchez J, Bock J, Hofmann WK and Baldus
CD: ERG induces a mesenchymal-like state associated with
chemoresistance in leukemia cells. Oncotarget. 5:351–362. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hagen RM, Adamo P, Karamat S, Oxley J,
Aning JJ, Gillatt D, Persad R, Ladomery MR and Rhodes A:
Quantitative analysis of ERG expression and its splice isoforms in
formalin-fixed, paraffin-embedded prostate cancer samples:
Association with seminal vesicle invasion and biochemical
recurrence. Am J Clin Pathol. 142:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
